These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36565735)

  • 1. Should Oncogene Testing Be Performed Before Induction Immunotherapy?
    Wright CD
    Ann Thorac Surg; 2023 Oct; 116(4):711. PubMed ID: 36565735
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogene-associated tumor antigens as targets for immunotherapy.
    Hellström KE; Hellström I
    FASEB J; 1989 Apr; 3(6):1715-22. PubMed ID: 2649402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
    Otano I; Ucero AC; Zugazagoitia J; Paz-Ares L
    Nat Rev Clin Oncol; 2023 Mar; 20(3):143-159. PubMed ID: 36639452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Oncogene Interference to Neutrophil Immune Modulation.
    Bronte V
    Immunity; 2017 Oct; 47(4):613-615. PubMed ID: 29045894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?
    Abrash EW; Calabrese JM
    Mol Cell; 2022 Jul; 82(13):2353-2355. PubMed ID: 35803214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.
    Bernards R; Destree A; McKenzie S; Gordon E; Weinberg RA; Panicali D
    Proc Natl Acad Sci U S A; 1987 Oct; 84(19):6854-8. PubMed ID: 3477812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies.
    Curiel DT
    Adv Pharmacol; 1997; 40():51-84. PubMed ID: 9217923
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3T3 cells causes intracellular alkalinisation and cell-cycle progression.
    Doppler W; Jaggi R; Groner B
    Gene; 1987; 54(1):147-53. PubMed ID: 3038697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review.
    Song Y; Bai Y; Wang J; Xu G; Wang T; Zhang B
    Endocr J; 2023 Feb; 70(2):223-228. PubMed ID: 36351596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes.
    Anders K; Blankenstein T
    Clin Cancer Res; 2013 Jan; 19(2):320-6. PubMed ID: 23197254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.
    Shapira S; Kazanov D; Weisblatt S; Starr A; Arber N; Kraus S
    J Biol Chem; 2011 Nov; 286(47):40548-55. PubMed ID: 21976680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
    Chen S; Duan H; Sun G
    Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice.
    Ichihara M; Iwamoto T; Isobe K; Takahashi M; Nakayama A; Pu M; Dai Y; Parashar A; Ohkus K; Kato M
    Br J Cancer; 1995 Apr; 71(4):808-13. PubMed ID: 7710948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hairy powers of oncogenes: from biological function to cancer therapy.
    Polyak K
    Cancer Biol Ther; 2003; 2(5):592-4. PubMed ID: 14614334
    [No Abstract]   [Full Text] [Related]  

  • 16. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
    Yang W; Han B; Chen Y; Geng F
    Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviruses and the genetics of cancer.
    Temin HM
    Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):543-5. PubMed ID: 2843485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.
    Petroni G; Buqué A; Coussens LM; Galluzzi L
    Nat Rev Drug Discov; 2022 Jun; 21(6):440-462. PubMed ID: 35292771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential induction of cytolytic susceptibility by E1A, myc, and ras oncogenes in immortalized cells.
    Cook JL; May DL; Wilson BA; Walker TA
    J Virol; 1989 Aug; 63(8):3408-15. PubMed ID: 2526229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenes-antioncogenes and virus therapy of cancer.
    Sinkovics JG
    Anticancer Res; 1989; 9(5):1281-90. PubMed ID: 2556069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.